Literature DB >> 28546336

The Value of 18F-FDG PET/CT in Diagnosis and During Follow-up in 273 Patients with Chronic Q Fever.

Ilse J E Kouijzer1,2,3, Linda M Kampschreur4, Peter C Wever5, Corneline Hoekstra6, Marjo E E van Kasteren7, Monique G L de Jager-Leclercq8, Marrigje H Nabuurs-Franssen9, Marjolijn C A Wegdam-Blans10, Heidi S M Ammerlaan11, Jacqueline Buijs12, Lioe-Fee de Geus-Oei3,13, Wim J G Oyen14, Chantal P Bleeker-Rovers15,2.   

Abstract

In 1%-5% of all acute Q fever infections, chronic Q fever develops, mostly manifesting as endocarditis, infected aneurysms, or infected vascular prostheses. In this study, we investigated the diagnostic value of 18F-FDG PET/CT in chronic Q fever at diagnosis and during follow-up.
Methods: All adult Dutch patients suspected of chronic Q fever who were diagnosed since 2007 were retrospectively included until March 2015, when at least one 18F-FDG PET/CT scan was obtained. Clinical data and results from 18F-FDG PET/CT at diagnosis and during follow-up were collected. 18F-FDG PET/CT scans were prospectively reevaluated by 3 nuclear medicine physicians using a structured scoring system.
Results: In total, 273 patients with possible, probable, or proven chronic Q fever were included. Of all 18F-FDG PET/CT scans performed at diagnosis, 13.5% led to a change in diagnosis. Q fever-related mortality rate in patients with and without vascular infection based on 18F-FDG PET/CT was 23.8% and 2.1%, respectively (P = 0.001). When 18F-FDG PET/CT was added as a major criterion to the modified Duke criteria, 17 patients (1.9-fold increase) had definite endocarditis. At diagnosis, 19.6% of 18F-FDG PET/CT scans led to treatment modification. During follow-up, 57.3% of 18F-FDG PET/CT scans resulted in treatment modification.
Conclusion: 18F-FDG PET/CT is a valuable technique in diagnosis of chronic Q fever and during follow-up, often leading to a change in diagnosis or treatment modification and providing important prognostic information on patient survival.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  18F-FDG PET/CT; Q fever; endocarditis; vascular infection

Mesh:

Substances:

Year:  2017        PMID: 28546336     DOI: 10.2967/jnumed.117.192492

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

1.  Hemodialysis vascular graft as a focus of persistent Q fever.

Authors:  Vincent Ernest; Serge Cammilleri; Philippe Amabile; Mathilde Fedi; Stéphane Burtey; Clarissa Von Kotze; Marion Pelletier; Valérie Moal; Eric Guedj; Cindy Perron; Raafat Boustani; Yvon Berland; Philippe Brunet; Didier Raoult; Pierre-Edouard Fournier; Noémie Jourde-Chiche
Journal:  Infection       Date:  2018-10-27       Impact factor: 3.553

2.  18F-Fluorodeoxyglucose positron emission tomography/computed tomography as a diagnostic and follow-up tool in Coxiella burnetii endocarditis of prosthetic valve and aortic valved tube: a case report.

Authors:  Elisa Ricciardi; Alessandro Moscatelli; Marco Berruti; Maria Isabella Donegani; Malgorzata Karolina Mikulska; Aldo Pende
Journal:  Eur Heart J Case Rep       Date:  2021-05-17

3.  Serum Bactericidal Activity Levels Monitor to Guide Intravenous Dalbavancin Chronic Suppressive Therapy of Inoperable Staphylococcal Prosthetic Valve Endocarditis: A Case Report.

Authors:  Martina Spaziante; Cristiana Franchi; Gloria Taliani; Antonio D'Avolio; Valeria Pietropaolo; Elisa Biliotti; Rozenn Esvan; Mario Venditti
Journal:  Open Forum Infect Dis       Date:  2019-09-30       Impact factor: 3.835

4.  Zoonotic risks of pathogens from sheep and their milk borne transmission.

Authors:  René van den Brom; Aarieke de Jong; Erik van Engelen; Annet Heuvelink; Piet Vellema
Journal:  Small Rumin Res       Date:  2020-05-15       Impact factor: 1.611

5.  Screening for Q Fever in Patients Undergoing Transcatheter Aortic Valve Implantation, Israel, June 2018-May 2020.

Authors:  Nesrin Ghanem-Zoubi; Mical Paul; Moran Szwarcwort; Yoram Agmon; Arthur Kerner
Journal:  Emerg Infect Dis       Date:  2021-08       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.